Trials / Completed
CompletedNCT01565434
Erythrocyte Complement Receptor 1 and Alzheimer Disease
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 200 (actual)
- Sponsor
- CHU de Reims · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
Main objective: investigate whether a functional polymorphism of CR1 (length, number of binding sites in C4b C3b, erythrocyte density, rate of soluble CR1 ...) so determined genetic or acquired, is a susceptibility factor for the disease Alzheimer's.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | CR1 impact |
Timeline
- Start date
- 2012-02-01
- Completion
- 2015-04-01
- First posted
- 2012-03-28
- Last updated
- 2026-01-21
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT01565434. Inclusion in this directory is not an endorsement.